Does toxicity predict efficacy? insight into the mechanism of action of lapatinib

Journal of Clinical Oncology

Volumn 32, Issue 30, 2014, Pages 3458-3459

  Fontanella, Caterina ^a,b   Lederer, Bianca ^a   Nekljudova, Valentina ^c   Untch, Michael ^c   Von Minckwitz, Gunter ^a   Loibl, Sibylle ^a,d  

^a German Breast Group   (Germany)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

^d SANA KLINIKUM OFFENBACH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; ERLOTINIB; LAPATINIB; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; ECHOMAMMOGRAPHY; EVENT FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST CANCER; LETTER; SKIN; TREATMENT DURATION; TUMOR VOLUME; ADJUVANT THERAPY; BREAST NEOPLASMS; CHEMICALLY INDUCED; DRUG ERUPTIONS; DRUG-INDUCED LIVER INJURY; FEMALE; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DIARRHEA; DRUG ERUPTIONS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; NEOADJUVANT THERAPY; QUINAZOLINES;

EID: 84908406068     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.0499     Document Type: Letter

References (9)

1. Azim HA Jr, Agbor-Tarh D, Bradbury I, et al: Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: Analysis from the NeoALTTO trial. J Clin Oncol 31:4504-4511, 2013
2. Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 379:633-640, 2012
3. Untch M, Loibl S, Bischoff J, et al: Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (Gepar-Quinto, GBG 44): A randomised phase 3 trial. Lancet Oncol 13:135-144, 2012
4. Saif MW, Merikas I, Tsimboukis S, et al: Erlotinib-induced skin rash: Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP 9:267-274, 2008
5. Peré z-Soler R, Saltz L: Cutaneous adverse effects with HER1/EGFRtargeted agents: Is there a silver lining? J Clin Oncol 23:5235-5246, 2005
6. Nardone B, Nicholson K, Newman M, et al: Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. Clin Cancer Res 16:4452-4460, 2010
7. Finn RS, Press MF, Dering J, et al: Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol 27:3908-3915, 2009
8. Press MF, Finn RS, Cameron D, et al: HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 14:7861-7870, 2008
9. DeFazio-Eli L, Strommen K, Dao-Pick T, et al: Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: Applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res 13:R44, 2011